Part 6/8:
As investors reflect on the less-than-stellar performance of CAR-T stocks in 2018, looking ahead to 2019 offers a glimpse of potential stabilization and growth. Despite the disappointing sales figures, emerging data is providing renewed hope. For example, research presented at the American Society of Hematology (ASH) conference revealed promising durability of response rates. In particular, Yescarta demonstrated that 39% of patients maintained their response after two years, a significant finding that could bolster confidence among physicians and payers.